Literature DB >> 23629471

Urological cancer: second-line option for metastatic RCC.

Vanessa Marchesi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23629471     DOI： 10.1038/nrclinonc.2013.74

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  2 in total

1.  Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.

Authors:  Robert J Motzer; Bernard Escudier; Piotr Tomczak; Thomas E Hutson; M Dror Michaelson; Sylvie Negrier; Stephane Oudard; Martin E Gore; Jamal Tarazi; Subramanian Hariharan; Connie Chen; Brad Rosbrook; Sinil Kim; Brian I Rini
Journal:  Lancet Oncol       Date:  2013-04-16       Impact factor: 41.316

2.  Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial.

Authors:  D Cella; B Escudier; B Rini; C Chen; H Bhattacharyya; J Tarazi; B Rosbrook; S Kim; R Motzer
Journal:  Br J Cancer       Date:  2013-04-11       Impact factor: 7.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.